TURP with standard therapy for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a surgery called TURP (transurethral resection of the prostate) to the usual hormone therapy and chemotherapy can help men with metastatic prostate cancer that has spread to lymph nodes, bone, or other organs. The surgery helps relieve urinary symptoms and may improve how well the cancer responds to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been newly diagnosed with prostate cancer that has spread to lymph nodes, bone, or other organs (metastatic).
- You have a good performance status (ECOG 0 or 1), meaning you can do most daily activities without help.
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges.
- You do not have any active infections like HIV or hepatitis B or C.
- You have not had major surgery in the last 4 weeks or any history of seizures, severe heart problems, or other cancers in the past 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing if removing the prostate with surgery, after starting hormone therapy, helps men with advanced prostate cancer that has spread to many parts of the body. It aims to see if this approach improves outcomes compared to hormone therapy alone.
This study tests if removing the prostate and giving strong hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. It aims to improve how long patients live without the cancer worsening.
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
This study tests adding a targeted local treatment (like radiation or surgery) to standard hormone therapy for men with advanced prostate cancer that still shows up on a special scan. The goal is to see if this combination helps control the cancer better.
This trial tests if adding the drug rezvilutamide to standard hormone therapy, along with prostate removal surgery and precise radiation to cancer spots, helps men whose prostate cancer has spread to a limited number of places (no more than 10 spots, and not in organs like the liver or lungs).
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.